Given the survival benefit seen in ADMIRAL for gilteritinib in patients with combined NPM1 and DNMT3A mutations,8,19 we examined outcomes by the combination of mutations in these 2 genes in patients treated for FLT3-ITD AML. This evidence concerns the gene DNMT3A and acute myeloid leukemia.